Amazon launches One Medical GLP‑1 program

Amazon One Medical has started a nationwide weight-management program that puts GLP-1 prescribing inside its primary care system and links it to Amazon Pharmacy. (aboutamazon.com) (health.amazon.com) The program was announced April 21 and combines in-person care, virtual follow-ups, prescription management, and pharmacy fulfillment in one workflow. Amazon says the service is designed to treat obesity as a chronic condition rather than a one-time prescription. (aboutamazon.com) (fiercehealthcare.com) On its public sign-up page, Amazon says patients work with a dedicated provider, get ongoing follow-ups, and receive insurance and prior-authorization support. If a clinician prescribes treatment, the prescription can be sent to a preferred pharmacy, including Amazon Pharmacy. (health.amazon.com) Amazon lists branded options including Wegovy, Zepbound, the Zepbound KwikPen, and Eli Lilly’s oral drug Foundayo. The company says insured pricing can start as low as $25 a month, with cash-pay prices starting at $149 for oral drugs and $299 for injectables. (health.amazon.com) (cnbc.com) GLP-1 drugs are medicines that help people feel full longer and eat less, and they are now widely used for chronic weight management as well as diabetes care. Amazon’s pitch is that those drugs should sit inside routine primary care, where clinicians can also track blood pressure, blood sugar, side effects, and other medications. (health.amazon.com) (hitconsultant.net) That approach arrives as federal regulators are moving against a different part of the market: mass-marketed compounded GLP-1 products sold online. On February 6, the Food and Drug Administration said it intends to restrict active ingredients used in non-approved compounded GLP-1 drugs being marketed as alternatives to approved products. (fda.gov) On March 3, the FDA said it sent warning letters to 30 telehealth companies over false and misleading claims about compounded GLP-1 products. The agency said compounded drugs are not FDA-approved and cannot be marketed as the same as approved medicines or as generic versions. (fda.gov) The FDA added another signal on April 1, when it said compounders generally cannot make products that are essentially copies of commercially available drugs unless a prescriber documents a significant difference for an individual patient. The agency gave semaglutide-plus-vitamin B12 as one example that may still count as a copy. (fda.gov) Amazon is entering the market with branded drugs, a primary care network, and a pharmacy delivery business already under one roof. The bet is that easier prescribing, clearer pricing, and fewer handoffs will keep patients on treatment longer than the fragmented telehealth model regulators are now pressuring. (aboutamazon.com) (fda.gov)